CEBPA and lung adenocarcinoma: For example, in the case of lung adenocarcinoma, it would be possible to target specifically lung alveolar cells using the SFTPC (surfactant protein-C) promoter or CEBPα (CCAAT/enhancer-binding protein alpha) [16], dramatically reducing off-target effects when compared to classically used constitutive promoters.